The Judiciary Committee of the California State Senate on Tuesday passed SB761, legislation that would broadly regulate all online data collection and impose a "do not track" regulatory regime for online behavioral advertising.
We reported recently that the issue of reverse settlement payments to generic drug manufacturers was continuing to heat up this summer.
The U.S. Senate Judiciary Committee is considering legislation that, if passed, would amend the Clayton Act to “make illegal anti-competitive, anti-consumer patent payoffs in which brand name drug companies pay generic manufacturers millions of dollars to keep generic competition off the market.”
Federal and state regulators have had their say and now Congress may be stepping in to adopt measures aimed at eliminating investment fraud against seniors.
In Issue 4, page 12, we discussed several legislative initiatives that were introduced during the last Congress which, according to their sponsors, were aimed at preserving or enhancing competition in the pharmaceutical industry.
On 15 February 2007, the Senate Judiciary Committee unanimously passed a bill, the “Preserve Access to Affordable Generics Act”, that would prohibit brand drug manufacturers from using out-of-court settlements known as reverse payments to delay generic entry into the market.